CD8A and cytomegalovirus infection: For the clinical correlate of reactivated HCMV infection associated with HSCT, our findings predict that pre-emptive CD8 T-cell immunotherapy, even though controlling CMV only transiently, can bridge the critical time of an immunocompromised state until immune reconstitution by HSCT takes over.